Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 (80μg Estradiol/4mg Progesterone and 160μg Estradiol/8mg Progesterone Intravaginal Rings) in Healthy PostMenopausal Women

NCT05418426 is registered in ClinicalTrials.gov with Daré Bioscience, Inc. as lead sponsor.

NCT NCT05418426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05418426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 (80μg Estradiol/4mg Progesterone and 160μg Estradiol/8mg Progesterone Intravaginal Rings) in Healthy PostMenopausal Women
Lead sponsor
Daré Bioscience, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 18, 2020
Completion date
January 27, 2022
Enrollment
34 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

vasomotor symptoms, vulvovaginal atrophy